Structure TherapeuticsGPCR
About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Employees: 183
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 3 (+2) [Q2]
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
62.59% more ownership
Funds ownership: 32.51% [Q1] → 95.1% (+62.59%) [Q2]
36% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 44
23% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $8.34M
15% more capital invested
Capital invested by funds: $981M [Q1] → $1.13B (+$151M) [Q2]
12% more funds holding
Funds holding: 151 [Q1] → 169 (+18) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Ananda Ghosh | 223%upside $60 | Buy Maintained | 7 Aug 2025 |
Guggenheim Seamus Fernandez | 385%upside $90 | Buy Maintained | 7 Aug 2025 |
JMP Securities Jonathan Wolleben | 369%upside $87 | Market Outperform Maintained | 7 Aug 2025 |
Cantor Fitzgerald Prakhar Agrawal | 250%upside $65 | Overweight Reiterated | 23 Jun 2025 |
Financial journalist opinion
